The present invention relates to a lyophilized preparation comprising two or more cancer antigen peptides derived from WT1 protein with an activity of inducing cytotoxic T lymphocytes for cancer peptide vaccine therapy.

Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated WT1 antigen. Vectors, compositions and vaccines comprising one or more nucleic acid sequences that encode a mutated WT1 antigen are disclosed. Methods of treating an individual who has a WT1-expressing tumor and methods of preventing a WT1-expressing tumor are disclosed. Mutated WT1 antigen is disclosed.

An immune enhancer comprising at least an interferon and a granulocyte-macrophage colony-stimulating factor, and an immunotherapeutic phar-maceutical composition comprising at least an antigen and the above-mentioned immune enhancers is disclosed. A preparation method of the immunotherapeutic pharmaceutical composition, the use of the immune enhancer and the immunotherapeutic pharmaceutical composition are also disclosed. The immune enhancer can be applied to disease and tumor treatments caused by viruses, bacteria, and other microorganisms.

Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated WT1 antigen. Vectors, compositions and vaccines comprising one or more nucleic acid sequences that encode a mutated WT1 antigen are disclosed. Methods of treating an individual who has a WT1-expressing tumor and methods of preventing a WT1-expressing tumor are disclosed. Mutated WT1 antigen is disclosed.

[Problem to be Solved] Provided is an effective and safe method for treating or preventing a cancer using aAVC. [Solution] The present invention finds suitable ranges of the dose of α-GalCer loaded on aAVC cell surface, and the amount of α-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.

Disclosed herein are compositions and methods for treating cancer and in particular vaccines that treat and provide protection against tumor growth.

This document provides methods and materials for expanding antigen-specific T cells (e.g., antigen-specific CD4.sup.+ T cells and/or antigen-specific CD8.sup.+ T cells) in culture. For example, methods and materials for performing a polyclonal stimulation step for a particular duration (e.g., from about 1 hour to about 48 hours) to increase the expansion of T cells having a desired antigen specificity are provided.

The present application provides methods of preparing tumor antigen-specific T cells comprising enriching activated T cells from a first co-culture comprising a first population of antigen-loaded dendritic cells loaded and a population of T cells, and co-culturing the enriched activated T cells with a second population of antigen-loaded dendritic cells. Also provided are methods of treating cancer in an individual using the tumor antigen-specific T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.

The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.

Disclosed herein are compositions and methods for treating cancer and in particular vaccines that treat and provide protection against tumor growth.